Immunic to Participate in Scientific and Investor Conferences in March

Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases [2] - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for relapsing and progressive multiple sclerosis, respectively [2] - Vidofludimus calcium has demonstrated therapeutic activity in phase 2 trials for relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis [2] - Other programs include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, currently in preclinical testing for gastrointestinal conditions [2] Upcoming Events - Immunic will participate in the 34th Annual Meeting of the Society for Virology from March 4-7, 2025, with two abstracts accepted for presentation [4] - The presentations will cover topics related to antiviral activity and will be accessible on Immunic's website [4] - Daniel Vitt, CEO of Immunic, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 12, 2025 [4]